期刊
DERMATOLOGY AND THERAPY
卷 11, 期 2, 页码 355-361出版社
ADIS INT LTD
DOI: 10.1007/s13555-021-00505-z
关键词
Atopic dermatitis; Daily practice; Dupilumab; Eczema; Severity
类别
This study confirms the long-term effectiveness and favorable safety profile of dupilumab in treating moderate-to-severe adult atopic dermatitis, showing significant improvement in disease severity scores and low discontinuation rates due to adverse events.
We have read with great interest the article by Kreeshan et al., which reported data on effectiveness and laboratory safety of dupilumab. We performed a retrospective study including 165 adult patients affected by moderate-to-severe atopic dermatitis (AD) and treated with dupilumab for at least 52 weeks. A significant improvement in eczema area severity index (EASI) score after 16 and 52 weeks of treatment with dupilumab was observed. The mean EASI score at baseline was 28.84 +/- 6.4 and significantly reduced to 10.05 +/- 8.00 at 16 weeks (p < 0.001), and to 3.04 +/- 4.73 at 52 weeks (p < 0.001), with a mean percentage reduction of 65.15% and 89.45%, respectively. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores (P-NRS, S-NRS and DLQI). Furthermore, no patient discontinued the drug because of inefficacy. Fifty-seven out of 165 (34.54%) patients reported at least one adverse event (AE) during the 52-week treatment. Our study confirms that dupilumab can represent a long-term treatment for moderate-to-severe adult AD, beyond 16 weeks. In our experience, dupilumab demonstrated a favourable safety profile at 52 weeks and only a few patients had to discontinue the treatment because of AEs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据